Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.22.1
Condensed Consolidated Statements of Cash Flows - USD ($)
6 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities    
Net loss $ (17,652,845) $ (9,588,000)
Adjustments to reconcile net loss to net cash used in operating activities    
Stock-based compensation 1,746,032 2,118,693
Change in fair value of warrant liabilities 0 (720,709)
Depreciation and amortization 372,407 151,418
Loss on marketable securities 30 15,006
Loss on disposal of fixed assets 0 0
Equity in losses on equity method investment 415,744 61,539
Gain on sale of intellectual property 0 (316,724)
Amortization of right-of-use assets 225,952 0
Changes in operating assets and liabilities    
Prepaid insurance, other prepaid expenses and current assets 773,506 122,878
Long-term prepaid insurance 0 96,834
Security deposit (19,600) (253,565)
Other long-term assets 160,423 0
Accounts payable (252,612) 436,646
Accrued expenses and other current liabilities 954,641 574,460
Operating lease liability (184,537) 0
Net cash used in operating activities (13,460,859) (7,301,524)
Cash flows from investing activities    
Purchase of laboratory and office equipment (272,287) (402,890)
Purchase of marketable securities (14,986,818) (29,996,904)
Sale of marketable securities 14,986,788 29,981,898
Net cash used in investing activities (272,317) (417,896)
Cash flows from financing activities    
Principal payment of financed insurance (148,385) (138,557)
Principal payment of finance lease liability (53,752) 0
Proceeds from exercise of stock options 42 112,446
Net cash used in financing activities (202,095) (26,111)
Net decrease in cash and cash equivalents (13,935,271) (7,745,531)
Cash and cash equivalents, beginning of period 52,893,387 31,992,283
Cash and cash equivalents, end of period 38,958,116 24,246,752
Supplemental disclosure of cash flow information:    
Cash paid for interest 0 10,400
Cash paid for income taxes 0 0
Non-cash investing and financing activities:    
Purchases of laboratory and office equipment in accounts payable 65,970 234,104
Preferred shares in DepYmed received as consideration for sale of intellectual property 0 316,724
Right-of-use asset obtained in exchange for operating lease liabilities $ 164,613 $ 0